Niraparib (Tablet)

DRUG2 trials

Sponsors

GlaxoSmithKline, Fudan University

Conditions

NeoplasmsOvarian Cancer

Phase 1

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

TerminatedNCT04544995

GlaxoSmithKlineNeoplasms

Start: 2020-10-06End: 2025-04-23Updated: 2026-01-21

Unknown Phase

Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer

RecruitingNCT07783022

Fudan UniversityOvarian Cancer

Start: 2024-12-01End: 2027-11-30Target: 1920Updated: 2026-08-24

Related Papers

Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.

Journal of Clinical Oncology2023-06-013 citations